Dyadic International, Inc. (NASDAQ: DYAI) – We are a global biotechnology company focused on further improving and leveraging the patented and proprietary C1 expression system to help bring biologic vaccines and drugs to market faster, in greater volumes, at lower cost, and with new properties to drug developers and manufacturers to improve access and cost to patients and the healthcare system – but most importantly to save lives.
“Without the ability to mass-produce whether it be a vaccine or an antibody we’re not getting anywhere soon and at the cost that the world can afford.”
RESEARCH REPORT $11.00 PRICE TARGET
*Client, see past reports for full disclosure and disclaimer details.
